Clinigen Group has launched its Japanese business with the opening of an office in Tokyo. The establishment of Clinigen KK further expands the group's presence in Asia, following Clinigen's acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen KK will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.
+0.50p (+0.06%)delayed 07:50AM